Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 49-58

  Kaye, S B ^a   Colombo, N ^b   Monk, B J ^c   Tjulandin, S ^d   Kong, B ^e   Roy, M ^f   Chan, S ^g   Filipczyk Cisarz, E ^h   Hagberg, H ⁱ   Vergote, I ^j   Lebedinsky, C ^k   Parekh, T ^l   Santabarbara P ^k   Park, Y C ^l   Nieto, A ^k   Poveda, A ^m  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e SHANDONG UNIVERSITY   (China)

^f Department of Gynecologic Oncology   (Canada)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h Oncological Center   (Poland)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k PHARMAMAR S A   (Spain)

^l JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^m Valencian Institute of Oncology   (Spain)

more..

Author keywords

Pegylated liposomal doxorubicin; Platinum free interval; Relapsed ovarian cancer; Trabectedin

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; TRABECTEDIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISCERAL METASTASIS;

EID: 78650312260     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq353     Document Type: Article

References (28)

1. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
2. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-2276.
3. Ganjoo KN, Patel SR. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother 2009; 10: 2735-2743.
4. Le Cesne A, Domont J, Cioffi A et al. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today (Barc) 2009; 45: 403-421.
5. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-1874.
6. Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinumbased regimens. Br J Cancer 2007; 97: 1618-1624.
7. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-1802.
8. European Medicines Agency (EMA). Assessment report for Yondelis. International non-proprietary name/Common name: trabectedin Procedure. No.EMEA/H/C/000773/II/0008. http://www.ema.europa.eu/humandocs/PDFs/EPAR/yondelis/EMEA-H-773-II-08-AR.pdf. EMEA/640507/2009 2009.
9. Monk BJ, Herzog T, Kaye S et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol 2008; 19: viii1-viii4, LBA4; doi:10.1093/annonc/mdn1649.
10. Monk BJ, Herzog TJ, Kaye S et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
11. Poveda A, Tjulandin S, Kong B et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study. J Clin Oncol 2010; 28 (15s): abstract 5012.
12. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinumsensitive (platinum-free interval 6-12 Months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010; doi:10.1093/annonc/mdq352.
13. Horowitz NS, Hua J, Gibb RK et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004; 94: 67-73.
14. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999; 4: 87-94.
15. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209-216.
16. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-1588.
17. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-653.
18. Kaye S. Management of partially platinum-sensitive relapsed ovarian cancer. Eur J Canc Suppl 2008; 6: 16-21.
19. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006; 33: S12-S16.
20. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinumsensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009; 19 (Suppl 2): S63-S67.
21. Leitao MM, Jr., Hummer A, Dizon DS et al. Platinum retreatment of platinumresistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003; 91: 123-129.
22. Nguyen TT, Wright JD, Powell MA et al. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer 2008; 18: 1194-1199.
23. Brewer CA, Blessing JA, Nagourney RA et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 103: 446-450.
24. Ray-Coquard I, Weber B, Cretin J et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 2009; 100: 601-607.
25. Lorusso D, Di Stefano A, Fanfani F, Scambia G. Role of gemcitabine in ovarian cancer treatment. Ann Oncol 2006; 17 (Suppl 5): v188-v194.
26. Pignata S, Ferrandina G, Scarfone G et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 2006; 71: 320-326.
27. D'Incalci M, Erba E, Damia G et al. Unique features of the mode of action of ET-743. Oncologist 2002; 7: 210-216.
28. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003; 90: S39-S44.